Cell-to-cell spread of HIV-1 and evasion of neutralizing antibodies

Vaccine

Volumn 31, Issue 49, 2013, Pages 5789-5797

  Schiffner, Torben ^a   Sattentau, Quentin J ^a   Duncan, Christopher J A ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Broadly neutralizing; CD4 binding site; Dendritic cell; Envelope; Infectious synapse; Macrophage; T cell; Virological synapse

Indexed keywords

GAG PROTEIN; NEUTRALIZING ANTIBODY; VIRUS ENVELOPE PROTEIN;

ANTIBODY RESPONSE; CD4+ T LYMPHOCYTE; CELL STRUCTURE; ENDOSOME; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE EVASION; INTRACELLULAR TRANSPORT; MACROPHAGE; MYELOID DENDRITIC CELL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN EXPRESSION; PROTEIN SECRETION; REVIEW; SIGNAL TRANSDUCTION; SYNCYTIUM; VIRION; VIROLOGICAL SYNAPSE; VIRUS CELL INTERACTION; VIRUS ENTRY; VIRUS NEUTRALIZATION; VIRUS TRANSMISSION;

BROADLY NEUTRALIZING; CD4-BINDING SITE; DENDRITIC CELL; ENVELOPE; INFECTIOUS SYNAPSE; MACROPHAGE; T CELL; VIROLOGICAL SYNAPSE;

ANTIBODIES, NEUTRALIZING; DENDRITIC CELLS; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; EPITOPES; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; IMMUNE EVASION; IMMUNOLOGICAL SYNAPSES;

EID: 84887618532     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.10.020     Document Type: Review

References (112)

1. Nabel G.J. Rational design of vaccines for AIDS and influenza. Trans Am Clin Climatol Assoc 2012, 123:9-15. [discussion 15-6].
2. Kwong P.D., Mascola J.R., Nabel G.J. Rational design of vaccines to elicit broadly neutralizing antibodies to HIV-1. Cold Spring Harb Perspect Med 2011, (September (1)):a007278.
3. Burton D.R., Ahmed R., Barouch D.H., Butera S.T., Crotty S., Godzik A., et al. A blueprint for HIV vaccine discovery. Cell Host Microbe 2012, 12(October (4)):396-407.
4. Schiffner T., Sattentau Q.J., Dorrell L. Development of prophylactic vaccines against HIV-1. Retrovirology 2013, 10:72.
5. Zanetti G., Briggs J.A., Grunewald K., Sattentau Q.J., Fuller S.D. Cryo-electron tomographic structure of an immunodeficiency virus envelope complex in situ. PLoS Pathog 2006, 2(August (8)):e83.
6. Liu J., Bartesaghi A., Borgnia M.J., Sapiro G., Subramaniam S. Molecular architecture of native HIV-1 gp120 trimers. Nature 2008, 455(September (7209)):109-113.
7. Hu G., Liu J., Taylor K.A., Roux K.H. Structural comparison of HIV-1 Envelope Spikes with and without the V1/V2 Loop. J Virol 2011, 86(March (6)):2741-2750.
8. White T.A., Bartesaghi A., Borgnia M.J., Meyerson J.R., de la Cruz M.J., Bess J.W., et al. Molecular architectures of trimeric SIV and HIV-1 envelope glycoproteins on intact viruses: strain-dependent variation in quaternary structure. PLoS Pathog 2010, 6(12):e1001249.
9. Wu X., Yang Z.Y., Li Y., Hogerkorp C.M., Schief W.R., Seaman M.S., et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 2010, 329(August (5993)):856-861.
10. Walker L.M., Huber M., Doores K.J., Falkowska E., Pejchal R., Julien J.P., et al. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 2011, 477(September (7365)):466-470.
11. Walker L.M., Phogat S.K., Chan-Hui P.Y., Wagner D., Phung P., Goss J.L., et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 2009, 326(October (5950)):285-289.
12. Klein F., Gaebler C., Mouquet H., Sather D.N., Lehmann C., Scheid J.F., et al. Broad neutralization by a combination of antibodies recognizing the CD4 binding site and a new conformational epitope on the HIV-1 envelope protein. J Exp Med 2012, 209(July (8)):1469-1479.
13. Falkowska E., Ramos A., Feng Y., Zhou T.Q., Moquin S., Walker L.M., et al. PGV04, an HIV-1 gp120 CD4 binding site antibody, is broad and potent in neutralization but does not induce conformational changes characteristic of CD4. J Virol 2012, 86(April (8)):4394-4403.
14. Huang J., Ofek G., Laub L., Louder M.K., Doria-Rose N.A., Longo N.S., et al. Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature 2012, 491(November (7424)):406-412.
15. Moldt B., Rakasz E.G., Schultz N., Chan-Hui P.Y., Swiderek K., Weisgrau K.L., et al. Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo. Proc Natl Acad Sci U S A 2012, 109(November (46)):18921-18925.
16. Burton D.R., Hessell A.J., Keele B.F., Klasse P.J., Ketas T.A., Moldt B., et al. Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody. Proc Natl Acad Sci U S A 2011, 108(July (27)):11181-11186.
17. Hessell A.J., Rakasz E.G., Poignard P., Hangartner L., Landucci G., Forthal D.N., et al. Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal shiv challenge even at low serum neutralizing titers. PLoS Pathog 2009, 5(May (5)).
18. Parren P.W.H.I., Marx P.A., Hessell A.J., Luckay A., Harouse J., Cheng-Mayer C., et al. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J Virol 2001, 75(September (17)):8340-8347.
19. Hessell A.J., Rakasz E.G., Tehrani D.M., Huber M., Weisgrau K.L., Landucci G., et al. Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L. J Virol 2010, 84(February (3)):1302-1313.
20. Trkola A., Kuster H., Rusert P., Joos B., Fischer M., Leemann C., et al. Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nat Med 2005, 11(June (6)):615-622.
21. Klein F., Halper-Stromberg A., Horwitz J.A., Gruell H., Scheid J.F., Bournazos S., et al. HIV therapy by a combination of broadly neutralizing antibodies in humanized mice. Nature 2012, 492(December (7427)):118-122.
22. Zhou T.Q., Georgiev I., Wu X.L., Yang Z.Y., Dai K.F., Finzi A., et al. Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science 2010, 329(August (5993)):811-817.
23. Burton D.R., Pyati J., Koduri R., Sharp S.J., Thornton G.B., Parren P.W.H.I., et al. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal-antibody. Science 1994, 266(November (5187)):1024-1027.
24. Zhou T.Q., Xu L., Dey B., Hessell A.J., Van Ryk D., Xiang S.H., et al. Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature 2007, 445(February (7129)):732-737.
25. Buchacher A., Predl R., Strutzenberger K., Steinfellner W., Trkola A., Purtscher M., et al. Generation of human monoclonal-antibodies against HIV-1 proteins - electrofusion and Epstein-Barr-Virus transformation for peripheral-blood lymphocyte immortalization. AIDS Res Human Retroviruses 1994, 10(April (4)):359-369.
26. Sanders R.W., Venturi M., Schiffner L., Kalyanaraman R., Katinger H., Lloyd K.O., et al. The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120. J Virol 2002, 76(July (14)):7293-7305.
27. Pejchal R., Doores K.J., Walker L.M., Khayat R., Huang P.S., Wang S.K., et al. A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield. Science 2011, 334(November (6059)):1097-1103.
28. Bonsignori M., Hwang K.K., Chen X., Tsao C.Y., Morris L., Gray E., et al. Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors. J Virol 2011, 85(October (19)):9998-10009.
29. Kwong P.D., Wyatt R., Majeed S., Robinson J., Sweet R.W., Sodroski J., et al. Structures of HIV-1 gp120 envelope glycoproteins from laboratory-adapted and primary isolates. Structure 2000, 8(December (12)):1329-1339.
30. Kwong P.D., Wyatt R., Robinson J., Sweet R.W., Sodroski J., Hendrickson W.A. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 1998, 393(June (6686)):648-659.
31. Thali M., Moore J.P., Furman C., Charles M., Ho D.D., Robinson J., et al. Characterization of conserved human-immunodeficiency-virus type-1 gp120 neutralization epitopes exposed upon gp120-CD4 binding. J Virol 1993, 67(July (7)):3978-3988.
32. Sun Z.Y.J., Oh K.J., Kim M.Y., Yu J., Brusic V., Song L.K., et al. HIV-1 broadly neutralizing antibody extracts its epitope from a kinked gp41 ectodomain region on the viral membrane. Immunity 2008, 28(January (1)):52-63.
33. Kwong P.D., Mascola J.R. Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies. Immunity 2012, 37(September (3)):412-425.
34. Wu X., Wang C., O'Dell S., Li Y., Keele B.F., Yang Z., et al. Selection pressure on HIV-1 envelope by broadly neutralizing antibodies to the conserved CD4-binding site. J Virol 2012, 86(May (10)):5844-5856.
35. Bar K.J., Tsao C.Y., Iyer S.S., Decker J.M., Yang Y., Bonsignori M., et al. Early low-titer neutralizing antibodies impede HIV-1 replication and select for virus escape. PLoS Pathog 2012, 8(5):e1002721.
36. Eisele E., Siliciano R.F. Redefining the viral reservoirs that prevent HIV-1 eradication. Immunity 2012, 37(September (3)):377-388.
37. Sattentau Q. Avoiding the void: cell-to-cell spread of human viruses. Nat Rev Microbiol 2008, 6(November (11)):815-826.
38. Gupta P., Balachandran R., Ho M., Enrico A., Rinaldo C. Cell-to-cell transmission of human immunodeficiency virus type 1 in the presence of azidothymidine and neutralizing antibody. J Virol 1989, 63(May (5)):2361-2365.
39. Jolly C., Kashefi K., Hollinshead M., Sattentau Q.J. HIV-1 cell to cell transfer across an Env-induced, actin-dependent synapse. J Exp Med 2004, 199(January (2)):283-293.
40. Groot F., Welsch S., Sattentau Q.J. Efficient HIV-1 transmission from macrophages to T cells across transient virological synapses. Blood 2008, 111(May (9)):4660-4663.
41. McDonald D., Wu L., Bohks S.M., KewalRamani V.N., Unutmaz D., Hope T.J. Recruitment of HIV and its receptors to dendritic cell-T cell junctions. Science 2003, 300(May (5623)):1295-1297.
42. Nejmeddine M., Bangham C.R. The HTLV-1 virological synapse. Viruses 2010, 2(July (7)):1427-1447.
43. Sattentau Q.J. Cell-to-cell spread of retroviruses. Viruses 2010, 2(June (6)):1306-1321.
44. Murooka T.T., Deruaz M., Marangoni F., Vrbanac V.D., Seung E., von Andrian U.H., et al. HIV-infected T cells are migratory vehicles for viral dissemination. Nature 2012, 490(October (7419)):283-287.
45. Sewald X., Gonzalez D.G., Haberman A.M., Mothes W. In vivo imaging of virological synapses. Nat Commun 2012, 3:1320.
46. Salle B., Brochard P., Bourry O., Mannioui A., Andrieu T., Prevot S., et al. Infection of macaques after vaginal exposure to cell-associated simian immunodeficiency virus. J Infect Dis 2010, 202(August (3)):337-344.
47. Haase A.T. Targeting early infection to prevent HIV-1 mucosal transmission. Nature 2010, 464(March (7286)):217-223.
48. Rerks-Ngarm S., Pitisuttithum P., Nitayaphan S., Kaewkungwal J., Chiu J., Paris R., et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009, 361(December (23)):2209-2220.
49. Haynes B.F., Gilbert P.B., McElrath M.J., Zolla-Pazner S., Tomaras G.D., Alam S.M., et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 2012, 366(April (14)):1275-1286.
50. Mothes W., Sherer N.M., Jin J., Zhong P. Virus cell-to-cell transmission. J Virol 2010, 84(September (17)):8360-8368.
51. Jolly C., Mitar I., Sattentau Q.J. Adhesion molecule interactions facilitate human immunodeficiency virus type 1-induced virological synapse formation between T cells. J Virol 2007, 81(December (24)):13916-13921.
52. Vasiliver-Shamis G., Dustin M.L., Hioe C.E. HIV-1 virological synapse is not simply a copycat of the immunological synapse. Viruses 2010, 2(May (5)):1239-1260.
53. Jolly C., Welsch S., Michor S., Sattentau Q.J. The regulated secretory pathway in CD4(+) T cells contributes to human immunodeficiency virus type-1 cell-to-cell spread at the virological synapse. PLoS Pathog 2011, 7(September (9)):e1002226.
54. Rudnicka D., Feldmann J., Porrot F., Wietgrefe S., Guadagnini S., Prevost M.C., et al. Simultaneous cell-to-cell transmission of human immunodeficiency virus to multiple targets through polysynapses. J Virol 2009, 83(June (12)):6234-6246.
55. Martin N., Sattentau Q. Cell-to-cell HIV-1 spread and its implications for immune evasion. Curr Opin HIV AIDS 2009, 4(March (2)):143-149.
56. Sourisseau M., Sol-Foulon N., Porrot F., Blanchet F., Schwartz O. Inefficient human immunodeficiency virus replication in mobile lymphocytes. J Virol 2007, 81(January (2)):1000-1012.
57. Geijtenbeek T.B., Kwon D.S., Torensma R., van Vliet S.J., van Duijnhoven G.C., Middel J., et al. DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells. Cell 2000, 100(March (5)):587-597.
58. Izquierdo-Useros N., Lorizate M., Puertas M.C., Rodriguez-Plata M.T., Zangger N., Erikson E., et al. Siglec-1 is a novel dendritic cell receptor that mediates HIV-1 trans-infection through recognition of viral membrane gangliosides. PLoS Biol 2012, 10(12):e1001448.
59. de Witte L., Bobardt M., Chatterji U., Degeest G., David G., Geijtenbeek T.B., et al. Syndecan-3 is a dendritic cell-specific attachment receptor for HIV-1. Proc Natl Acad Sci U S A 2007, 104(December (49)):19464-19469.
60. McDonald D. Dendritic cells and HIV-1 trans-infection. Viruses 2010, 2(August (8)):1704-1717.
61. Cavrois M., Neidleman J., Kreisberg J.F., Greene W.C. In vitro derived dendritic cells trans-infect CD4 T cells primarily with surface-bound HIV-1 virions. PLoS Pathog 2007, 3(January (1)):e4.
62. Frank I., Stossel H., Gettie A., Turville S.G., Bess J.W., Lifson J.D., et al. A fusion inhibitor prevents spread of immunodeficiency viruses, but not activation of virus-specific T cells, by dendritic cells. J Virol 2008, 82(June (11)):5329-5339.
63. Yu H.J., Reuter M.A., McDonald D. HIV traffics through a specialized, surface-accessible intracellular compartment during trans-infection of T cells by mature dendritic cells. PLoS Pathog 2008, 4(8):e1000134.
64. Felts R.L., Narayan K., Estes J.D., Shi D., Trubey C.M., Fu J., et al. 3D visualization of HIV transfer at the virological synapse between dendritic cells and T cells. Proc Natl Acad Sci U S A 2010, 107(July (30)):13336-13341.
65. Stein B.S., Gowda S.D., Lifson J.D., Penhallow R.C., Bensch K.G., Engleman E.G. pH-independent HIV entry into CD4-positive T cells via virus envelope fusion to the plasma membrane. Cell 1987, 49(June (5)):659-668.
66. Permanyer M., Ballana E., Este J.A. Endocytosis of HIV: anything goes. Trends Microbiol 2010, 18(December (12)):543-551.
67. Dale B.M., McNerney G.P., Thompson D.L., Hubner W., de Los Reyes K., Chuang F.Y., et al. Cell-to-cell transfer of HIV-1 via virological synapses leads to endosomal virion maturation that activates viral membrane fusion. Cell Host Microbe 2011, 10(December (6)):551-562.
68. Pais-Correia A.M., Sachse M., Guadagnini S., Robbiati V., Lasserre R., Gessain A., et al. Biofilm-like extracellular viral assemblies mediate HTLV-1 cell-to-cell transmission at virological synapses. Nat Med 2010, 16(January (1)):83-89.
69. Monel B., Beaumont E., Vendrame D., Schwartz O., Brand D., Mammano F. HIV cell-to-cell transmission requires the production of infectious virus particles and does not proceed through env-mediated fusion pores. J Virol 2012, 86(April (7)):3924-3933.
70. Martin N., Welsch S., Jolly C., Briggs J.A., Vaux D., Sattentau Q.J. Virological synapse-mediated spread of human immunodeficiency virus type 1 between T cells is sensitive to entry inhibition. J Virol 2010, 84(April (7)):3516-3527.
71. Massanella M., Puigdomenech I., Cabrera C., Fernandez-Figueras M.T., Aucher A., Gaibelet G., et al. Anti gp41 antibodies fail to block early events of virological synapses but inhibit HIV spread between T cells. AIDS 2009, 23(January (2)):183-188.
72. Sanchez-Palomino S., Massanella M., Carrillo J., Garcia A., Garcia F., Gonzalez N., et al. A cell-to-cell HIV transfer assay identifies humoral responses with broad neutralization activity. Vaccine 2011, 29(July (32)):5250-5259.
73. Abela I.A., Berlinger L., Schanz M., Reynell L., Gunthard H.F., Rusert P., et al. Cell-cell transmission enables HIV-1 to evade inhibition by potent CD4bs directed antibodies. PLoS Pathog 2012, 8(4):e1002634.
74. Durham N.D., Yewdall A.W., Chen P., Lee R., Zony C., Robinson J.E., et al. Neutralization resistance of HIV-1 virological synapse-mediated infection is regulated by the gp41 cytoplasmic tail. J Virol 2012, 86(July (14)):7484-7495.
75. Hubner W., McNerney G.P., Chen P., Dale B.M., Gordon R.E., Chuang F.Y., et al. Quantitative 3D video microscopy of HIV transfer across T cell virological synapses. Science 2009, 323(March (5922)):1743-1747.
76. Ketas T.J., Frank I., Klasse P.J., Sullivan B.M., Gardner J.P., Spenlehauer C., et al. Human immunodeficiency virus type 1 attachment, coreceptor, and fusion inhibitors are active against both direct and trans infection of primary cells. J Virol 2003, 77(February (4)):2762-2767.
77. Chen P., Hubner W., Spinelli M.A., Chen B.K. Predominant mode of human immunodeficiency virus transfer between T cells is mediated by sustained Env-dependent neutralization-resistant virological synapses. J Virol 2007, 81(November (22)):12582-12595.
78. Ganesh L., Leung K., Lore K., Levin R., Panet A., Schwartz O., et al. Infection of specific dendritic cells by CCR5-tropic human immunodeficiency virus type 1 promotes cell-mediated transmission of virus resistant to broadly neutralizing antibodies. J Virol 2004, 78(November (21)):11980-11987.
79. van Montfort T., Nabatov A.A., Geijtenbeek T.B., Pollakis G., Paxton W.A. Efficient capture of antibody neutralized HIV-1 by cells expressing DC-SIGN and transfer to CD4+T lymphocytes. J Immunol 2007, 178(March (5)):3177-3185.
80. Rodriguez-Plata M.T., Puigdomenech I., Izquierdo-Useros N., Puertas M.C., Carrillo J., Erkizia I., et al. The infectious synapse formed between mature dendritic cells and CD4+T cells is independent of the presence of the HIV-1 envelope glycoprotein. Retrovirology 2013, 10:42.
81. Sagar M., Akiyama H., Etemad B., Ramirez N., Freitas I., Gummuluru S. Transmembrane domain membrane proximal external region but not surface unit-directed broadly neutralizing HIV-1 antibodies can restrict dendritic cell-mediated HIV-1 trans-infection. J Infect Dis 2012, 205(April (8)):1248-1257.
82. Su B., Xu K., Lederle A., Peressin M., Biedma M.E., Laumond G., et al. Neutralizing antibodies inhibit HIV-1 transfer from primary dendritic cells to autologous CD4 T-lymphocytes. Blood 2012, 120(November (18)):3708-3717.
83. Heath S.L., Tew J.G., Szakal A.K., Burton G.F. Follicular dendritic cells and human immunodeficiency virus infectivity. Nature 1995, 377(October (6551)):740-744.
84. Frankel S.S., Steinman R.M., Michael N.L., Kim S.R., Bhardwaj N., Pope M., et al. Neutralizing monoclonal antibodies block human immunodeficiency virus type 1 infection of dendritic cells and transmission to T cells. J Virol 1998, 72(December (12)):9788-9794.
85. Joyner A.S., Willis J.R., Crowe J.E., Aiken C. Maturation-induced cloaking of neutralization epitopes on HIV-1 particles. PLoS Pathog 2011, 7(September (9)):e1002234.
86. Calarese D.A., Lee H.K., Huang C.Y., Best M.D., Astronomo R.D., Stanfield R.L., et al. Dissection of the carbohydrate specificity of the broadly neutralizing anti-HIV-1 antibody 2G12. Proc Natl Acad Sci U S A 2005, 102(September (38)):13372-13377.
87. Del Portillo A., Tripodi J., Najfeld V., Wodarz D., Levy D.N., Chen B.K. Multiploid inheritance of HIV-1 during cell-to-cell infection. J Virol 2011, 85(July (14)):7169-7176.
88. Sigal A., Kim J.T., Balazs A.B., Dekel E., Mayo A., Milo R., et al. Cell-to-cell spread of HIV permits ongoing replication despite antiretroviral therapy. Nature 2011, 477(September (7362)):95-98.
89. Zhong P., Agosto L.M., Ilinskaya A., Dorjbal B., Truong R., Derse D., et al. Cell-to-cell transmission can overcome multiple donor and target cell barriers imposed on cell-free HIV. PLoS ONE 2013, 8(1):e53138.
90. Russell R.A., Martin N., Mitar I., Jones E., Sattentau Q.J. Multiple proviral integration events after virological synapse-mediated HIV-1 spread. Virology 2013, 443(August (1)):143-149.
91. Duncan C.J., Russell R.A., Sattentau Q.J. High multiplicity HIV-1 cell-to-cell transmission from macrophages to CD4+T cells limits antiretroviral efficacy. AIDS 2013, 27(September (14)):2201-2206.
92. Permanyer M., Ballana E., Ruiz A., Badia R., Riveira-Munoz E., Gonzalo E., et al. Antiretroviral agents effectively block HIV replication after cell-to-cell transfer. J Virol 2012, 86(August (16)):8773-8780.
93. Welsch S., Groot F., Krausslich H.G., Keppler O.T., Sattentau Q.J. Architecture and regulation of the HIV-1 assembly and holding compartment in macrophages. J Virol 2011, 85(August (15)):7922-7927.
94. Koppensteiner H., Banning C., Schneider C., Hohenberg H., Schindler M. Macrophage internal HIV-1 is protected from neutralizing antibodies. J Virol 2012, 86(March (5)):2826-2836.
95. Binley J.M., Cayanan C.S., Wiley C., Schulke N., Olson W.C., Burton D.R. Redox-triggered infection by disulfide-shackled human immunodeficiency virus type 1 pseudovirions. J Virol 2003, 77(May (10)):5678-5684.
96. Sattentau Q.J., Zolla-Pazner S., Poignard P. Epitope exposure on functional, oligomeric HIV-1 gp41 molecules. Virology 1995, 206(January (1)):713-717.
97. Li Y., Migueles S.A., Welcher B., Svehla K., Phogat A., Louder M.K., et al. Broad HIV-1 neutralization mediated by CD4-binding site antibodies. Nat Med 2007, 13(September (9)):1032-1034.
98. Simek M.D., Rida W., Priddy F.H., Pung P., Carrow E., Laufer D.S., et al. Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm. J Virol 2009, 83(July (14)):7337-7348.
99. Vujcic L.K., Quinnan G.V. Preparation and characterization of human Hiv type-1 neutralizing reference sera. AIDS Res Human Retroviruses 1995, 11(July (7)):783-787.
100. Salazar-Gonzalez J.F., Salazar M.G., Keele B.F., Learn G.H., Giorgi E.E., Li H., et al. Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. J Exp Med 2009, 206(June (6)):1273-1289.
101. Ochsenbauer C., Edmonds T.G., Ding H., Keele B.F., Decker J., Salazar M.G., et al. Generation of transmitted/founder HIV-1 infectious molecular clones and characterization of their replication capacity in CD4 T lymphocytes and monocyte-derived macrophages. J Virol 2012, 86(March (5)):2715-2728.
102. Harris L.J., Skaletsky E., McPherson A. Crystallographic structure of an intact IgG1 monoclonal antibody. J Mol Biol 1998, 275(February (5)):861-872.
103. Saphire E.O., Parren P.W., Pantophlet R., Zwick M.B., Morris G.M., Rudd P.M., et al. Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design. Science 2001, 293(August (5532)):1155-1159.
104. Mao Y., Wang L., Gu C., Herschhorn A., Xiang S.H., Haim H., et al. Subunit organization of the membrane-bound HIV-1 envelope glycoprotein trimer. Nat Struct Mol Biol 2012, 19(September (9)):893-899.
105. Tran E.E., Borgnia M.J., Kuybeda O., Schauder D.M., Bartesaghi A., Frank G.A., et al. Structural mechanism of trimeric HIV-1 envelope glycoprotein activation. PLoS Pathog 2012, 8(7):e1002797.
106. Zhou T., Xu L., Dey B., Hessell A.J., Van Ryk D., Xiang S.H., et al. Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature 2007, 445(February (7129)):732-737.
107. Calarese D.A., Scanlan C.N., Zwick M.B., Deechongkit S., Mimura Y., Kunert R., et al. Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science 2003, 300(June (5628)):2065-2071.
108. Wu H., Kwong P.D., Hendrickson W.A. Dimeric association and segmental variability in the structure of human CD4. Nature 1997, 387(May (6632)):527-530.
109. Zhou T., Georgiev I., Wu X., Yang Z.Y., Dai K., Finzi A., et al. Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science 2010, 329(August (5993)):811-817.
110. Pettersen E.F., Goddard T.D., Huang C.C., Couch G.S., Greenblatt D.M., Meng E.C., et al. UCSF Chimera - a visualization system for exploratory research and analysis. J Comput Chem 2004, 25(October (13)):1605-1612.
111. Bryson S., Julien J.P., Hynes R.C., Pai E.F. Crystallographic definition of the epitope promiscuity of the broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2F5: vaccine design implications. J Virol 2009, 83(November (22)):11862-11875.
112. McLellan J.S., Pancera M., Carrico C., Gorman J., Julien J.P., Khayat R., et al. Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature 2011, 480(December (7377)):336-343.